B2Core Reveals Its Latest Updates: What’s New?
B2Core, the premier CRM solution trusted by brokers and exchanges around the globe, continues to push the boundaries of innovation with its most recent significant update. This update introduces several advanced features and streamlined operations, giving financial institutions more powerful capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230529005019/en/
Telegram Integration (Graphic: Business Wire)
Let's have a look at the most notable features.
1. Advanced Event Notification Module
A brand-new Event Notification module has been added to the B2Core Back Office, providing admin users with a vast array of customizable event notifications. With the available 27 choices, administrators may send out alerts for various situations, from withdrawal requests to successful registrations.
Notifications are sent out to admin users on time whenever an event occurs, allowing them to respond appropriately. Additionally, the system allows additional admin users to be added to the "Users" category to receive notifications.
For your convenience, the module's event notification channels include email, SMS, Slack, and now Telegram. The "System-Templates" tab is where administrators may adjust settings and select a notification method. All event notifications are simply accessible via the user card, ensuring that vital information is always readily available.
For additional information on the new Event Notifications module, visit the official B2Core documentation page. In addition, there is a detailed How-To Guide and the References page covering more details.
2. Telegram Integration
B2Core now supports integration with Telegram, giving users even more channels to receive alerts. To begin getting Telegram notifications, users first must link their Telegram chat ID profile to their B2Core Back Office account, which is done in the admin's card under "System – Users – Edit user."
Users may configure the appropriate template under the "System – Templates – Telegram" section after navigating to the admin's card. It is now much easier for users to get important notifications on time by adding the Telegram channel to the Event Notifications area.
Step-by-step instructions on creating a Telegram template, activating a Telegram bot, and locating your unique chat ID may be found in our comprehensive How-to articles, ensuring a seamless onboarding process.
3. Detailed cTrader Data
B2Core's cTrader account interface, recently updated, provides an unmatched amount of depth for traders. Equity, Balance, Leverage, Credit, and Free Funds are just a few indications that users may dig into for their current accounts.
In addition, users may examine graphical representations of equity indicators across different timeframes and at different scales to gain a deeper understanding of the data. Access to real-time information on user orders and open positions and extensive historical information on performed trades and other pertinent data is also easily accessible. With this intuitive interface, investors can get all the relevant trading data they need in one convenient location.
4. Simplified Bulk Deposits to Client Accounts
In response to user feedback, the latest update introduces a new feature that simultaneously simplifies the process of depositing funds into multiple accounts. Within the "Accounts" section, the "Update Balances" window allows users to add funds to various designated accounts by uploading a CSV file containing the Email, ID, and precise amount. This streamlined process eliminates manual input, saving time and effort.
Bottom Line
B2Core's latest update cements its position as the CRM solution for brokers and exchanges. Introducing the Event Notification Module, Telegram Integration, Enhanced cTrader Data, and Simplified Bulk Deposits to Client Accounts showcase B2Core's commitment to providing a comprehensive and streamlined platform. Stay tuned for more exciting new features as B2Core continues to drive innovation in the industry!
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230529005019/en/
Contact information
Artyom Goryushin
+44 2080 688 636
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Blue Matter Establishes New Capabilities in Biopharma Research & Development Led by Partner, Tara Austraat-Churik13.1.2026 16:01:00 EET | Press release
Blue Matter is pleased to announce that it has established a practice area dedicated to serving clients in biopharmaceutical Research & Development (R&D). The practice is led by Tara Austraat-Churik, a Partner who joined the firm in September 2025. Tara Austraat-Churik has been serving life science clients for more than 20 years. Her areas of expertise include strategy development and implementation, operating model and organizational design, and process optimization in R&D and Medical Affairs. Prior to joining Blue Matter, she served as Managing Director in R&D, Health, Science, and Wellness at EY. She has a robust background in consulting, which also includes roles at Booz Allen Hamilton, Navitas, WPP, and IBM. She holds a BA and MA from the University of Notre Dame and an MSc in Translational Medicine from the University of Edinburgh. The R&D practice, according to Austraat-Churik, exists to help biopharma companies simplify and accelerate the pathway to market. She adds, “R&D organ
Wasabi Raises $70M in New Equity to Power the Next Era of Data Infrastructure13.1.2026 16:00:00 EET | Press release
Wasabi Technologies, the Hot Cloud Storage company, today announced a $70 million equity funding round led by L2 Point Management with participation from Pure Storage and existing investors including Fidelity Management & Research Company. The new round values Wasabi at $1.8 billion and brings the company’s total funding to over $600 million. The capital will be used to accelerate Wasabi’s expansion into AI infrastructure, broaden its global footprint, and enhance its product portfolio to meet the growing data demands of enterprises and AI developers worldwide. “We’re ushering in the next generation of cloud storage, powering data-intensive workloads like generative AI and autonomous systems,” said David Friend, co-founder and CEO of Wasabi Technologies. “This funding underscores Wasabi’s strong market position and continued growth as enterprises and AI developers alike seek a better, more predictable alternative to the hyperscalers.” Wasabi disrupted the cloud storage model in 2017 wi
Armis Secures Italy’s Primary Public Healthcare Provider for the City of Naples as Cyber Threats Increase13.1.2026 15:00:00 EET | Press release
Armis, the cyber exposure management & security company, today announced that ASL Napoli 1 Centro, Italy’s primary public healthcare provider for the City of Naples, is securing its attack surface using Armis Centrix™, the Armis Cyber Exposure Management Platform. Prior to working with Armis, ASL Napoli 1 Centro did not have the tools or capabilities to monitor physical and virtual assets in real time, which posed a challenge for its security and compliance. Armis Centrix™ was deployed with a clear goal: to provide ASL Napoli 1 Centro with a comprehensive, real-time view of its connected biomedical inventory and the associated risks to the overall environment. “Time-to-value was practically immediate; Armis began delivering valuable information as soon as the system was activated and connected to our internal network,” said Fulvio Paone, Director of the ICT and Digital Transformation Unit at ASL Napoli 1 Centro. “Armis has given us visibility into a critical area. This isn’t just about
Opengear Introduces CM8000 and OM1300: Two New Paths to Network Resilience as Outages Surge13.1.2026 15:00:00 EET | Press release
Opengear, a Digi International company (NASDAQ, DGII), today announced two new additions to its Network Resilience Platform: the CM8000 Series and the OM1300 Series. These next generation devices deliver compact, flexible, and automation-ready out-of-band infrastructure designed for a time when outages are increasing and distributed sites continue to scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113807672/en/ Opengear Introduces CM8000 and OM1300: Two New Paths to Network Resilience as Outages Surge According to Opengear research, 84 percent of CIOs and CISOs have experienced a rise in outages over the past two years. The CM8000 Series and OM1300 Series were purpose-built to ensure that IT teams maintain access and control even when the production network is unavailable. The two series provide complementary approaches: CM8000 Series A serial-first recovery platform with integrated power control for core branches,
GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug13.1.2026 15:00:00 EET | Press release
The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced that they have entered into a collaboration and license agreement to pursue the development of Debio1453, a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae. With 82 million new cases each year, and the continued spread of multidrug-resistant N. gonorrhoeae strains, gonorrhea represents a global health crisis. This new partnership will help ensure that gonorrhea continues to be a treatable disease and will alleviate the risk of the emergence of future resistance, by ensuring that the antibiotic pipeline continues to be replenished. Gonorrhea caused by N. gonorrhoeae is currently in danger of becoming untreatable because of antimicrobial resistance (AMR). Having developed resistance to almost all antibiotics used to treat it, only one last recommended treatment, ceftriaxone, remains effective, and now we are seeing a growing number of cases that are
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom